Safety Profile of Chimeric Antigen Receptor T-cell Therapies in Diffuse Large B-cell Lymphoma: An Analysis of Real-World Adverse Event Reporting From the FDA Adverse Event Reporting System
Objective To compare the real-world safety profiles of lisocabtagene maraleucel (liso-cel) and axicabtagene ciloleucel (axi-cel) in patients with diffuse large B-cell lymphoma, leveraging data from the United States Food and Drug Administration Adverse Event Reporting System (FAERS) database. Patients and Methods Case...